Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Case Study: Leiomyosarcoma and Disseminated Metastases

July 12th 2018

Management of Oligometastases in Soft-Tissue Sarcoma

July 12th 2018

Case Study: Recurrent Synovial Sarcoma

July 12th 2018

Will Immunotherapy Work for Soft Tissue Sarcoma?

July 12th 2018

Targeted Therapies for Adult STS

July 12th 2018

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

July 12th 2018

Systemic Therapy Approaches for Soft-Tissue Sarcoma

July 12th 2018

Metastatic Soft Tissue Sarcoma Goals of Therapy

July 12th 2018

Chemotherapeutic Approaches for Locally Advanced STS

July 12th 2018

Peri-Operative Therapy for Adult Soft Tissue Sarcoma

July 12th 2018

Multidisciplinary Assessment is Critical for Soft Tissue Sarcoma

July 12th 2018

Lumps and Bumps Are Common, Sarcomas Are Rare

July 12th 2018

Novel Cancer Vaccine May Improve Survival in Synovial Sarcoma

June 26th 2018

Investigators are hopeful that CMB305, a vaccine that boosts the immune response to tumor cells expressing the antigen NY-ESO-1, can improve survival outcomes for patients with synovial sarcoma.

Singh Discusses Developments in Uterine Sarcoma

June 19th 2018

Arun S. Singh, MD, discusses current and emerging treatment strategies for patients with uterine leiomyosarcoma and other sarcomas.

Dr. Singh on the Use of Chemotherapy in Patients With Uterine Leiomyosarcomas

June 18th 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the use of chemotherapy in patients with uterine leiomyosarcomas.

Dr. Singh on Drug Development for Patients With Soft Tissue Sarcomas

May 31st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.

Inaugural Guidelines for Patients With HIV Aim to Expand Therapy Options

May 12th 2018

Specific guidance in the HIV-infected population was not previously available, partly because persons living with HIV were previously excluded from cancer clinical trials, creating a knowledge gap.

Dr. Chase on the Standard of Care for Uterine Leiomyosarcoma

May 9th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

Crizotinib Confirmed as Standard of Care for ALK+ Inflammatory Myofibroblastic Tumors

April 16th 2018

Treatment with crizotinib elicited an objective response rate of 50% for patients with ALK-positive advanced, inoperable inflammatory myofibroblastic tumor.

Larotrectinib Update Shows Durable Responses in TRK-positive Cancers

February 22nd 2018

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.